Literature DB >> 10435497

Evolution of motor fluctuations in Parkinson's disease: a longitudinal study over 6 years.

K A Reardon1, M Shiff, P A Kempster.   

Abstract

A prospective longitudinal 6-year study of 34 patients with Parkinson's disease from the time of initiation of drug treatment explored changes in the motor response to L-dopa over the early to mid disease course. Motor fluctuations developed in 41% after a mean L-dopa treatment interval of 25 months and dyskinesia developed in 53% after a mean of 15 months' treatment. Patients who developed fluctuations had a significantly better response to L-dopa than nonfluctuators. Nonfluctuators also had significantly greater "midline" motor disability affecting cranial and truncal muscles and gait. The development of motor fluctuations may simply reflect a retained capacity to respond to L-dopa as endogenous dopaminergic neurotransmission declines with progressive nigral cell loss. Many patients who show no sign of motor fluctuation 5 or 6 years into the disease course have a relatively blunted response to L-dopa. The proportion of such cases seems to correspond to the percentage that have coexisting striatal pathologic changes in postmortem studies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10435497     DOI: 10.1002/1531-8257(199907)14:4<605::aid-mds1009>3.0.co;2-h

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  7 in total

Review 1.  Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.

Authors:  R C Dodel; K Berger; W H Oertel
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  Functional improvement after subthalamic stimulation in Parkinson's disease: a non-equivalent controlled study with 12-24 month follow up.

Authors:  M Capecci; R A Ricciuti; D Burini; V G Bombace; L Provinciali; M Iacoangeli; M Scerrati; M G Ceravolo
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-06       Impact factor: 10.154

3.  An objective fluctuation score for Parkinson's disease.

Authors:  Malcolm K Horne; Sarah McGregor; Filip Bergquist
Journal:  PLoS One       Date:  2015-04-30       Impact factor: 3.240

4.  Long-term treatment of Parkinson's disease with levodopa and other adjunctive drugs.

Authors:  Yoshikuni Mizuno; Satoe Shimoda; Hideki Origasa
Journal:  J Neural Transm (Vienna)       Date:  2017-01-16       Impact factor: 3.575

5.  A conditioned response as a measure of impulsive-compulsive behaviours in Parkinson's disease.

Authors:  Andrew H Evans; Jade Kettlewell; Sarah McGregor; Katya Kotschet; Robert I Griffiths; Malcolm Horne
Journal:  PLoS One       Date:  2014-02-24       Impact factor: 3.240

Review 6.  Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist.

Authors:  Jinglin Zhang; Louis Chew-Seng Tan
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

7.  Restoration of the Dopamine Transporter through Cell Therapy Improves Dyskinesia in a Rat Model of Parkinson's Disease.

Authors:  D Tomas; D Stanic; H K Chua; K White; W C Boon; M Horne
Journal:  PLoS One       Date:  2016-04-14       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.